Sign In
Buy LCTX
$1.20
-0.0100 (-0.83%)
At Close: Jun 03, 2026
Lineage Cell Therapeutics Q1 Earnings Call Highlights
07:11pm, Friday, 15'th May 2026
Lineage Cell Therapeutics NYSEAMERICAN: LCTX reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program i
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
09:50pm, Tuesday, 12'th May 2026
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
06:11pm, Tuesday, 12'th May 2026
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
04:01pm, Tuesday, 12'th May 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
08:00am, Tuesday, 05'th May 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
08:00am, Monday, 04'th May 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf
Lineage Announces Formation of Scientific Advisory Board
08:00am, Monday, 13'th Apr 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned
Defender Capital LLC. Buys Shares of 6,829,099 Lineage Cell Therapeutics, Inc. $LCTX
04:45am, Thursday, 26'th Mar 2026
Defender Capital LLC. bought a new stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) in the undefined quarter, according to its most recent disclosure with the Securities and Exch
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
08:00am, Tuesday, 24'th Mar 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic
Lineage Cell Therapeutics Q4 Earnings Call Highlights
01:02am, Sunday, 08'th Mar 2026
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used its quarterly conference call to highlight a longer cash runway following recent warrant exercises, progress in manufacturing capabilities, and early
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
09:45pm, Thursday, 05'th Mar 2026
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
Lineage Cell (LCTX) Reports Break-Even Earnings for Q4
06:30pm, Thursday, 05'th Mar 2026
Lineage Cell (LCTX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.01 per share a year ago.
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
04:01pm, Thursday, 05'th Mar 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
08:00am, Thursday, 26'th Feb 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or �
